

## Publications by Janet R Wade

1. B Wade & JR Wade, 1983.  
Drugs and the elderly: Does the responsibility stop with the prescriber.  
Nursing Mirror, 17-21, 4th May.
2. B Wade, JR Wade, J Bell et al, 1986.  
Drug use in residential settings.  
In 'Residential care for elderly people'. Background papers and synopses of research, DHSS, Seminar on residential care. HMSO, 173-181.
3. B Silke, DJM Graham, SP Verna, G Reynolds, MA Frais, JR Wade, & SH Taylor., 1986.  
Pharmacokinetic and radionuclide studies of nicardipine in coronary artery disease.  
Eur. J. Clin. Pharmacol., **29**, 651-657.
4. JR Wade, PA Meredith, DM Hughes & HL Elliott, 1992.  
The effect of saturation of ACE binding sites on the pharmacokinetics of enalaprilat in man.  
Br. J. Clin. Pharmacol., **33**, 155-160.
5. JR Wade, AW Kelman, DJ Kerr, J Robert & B Whiting, 1992.  
Variability in the pharmacokinetics of epirubicin - A population analysis.  
Cancer Chem. Pharmacol., **29**, 391-395.
6. JR Wade, DM Hughes, AW Kelman, CA Howie & PA Meredith, 1993.  
A novel statistical approach for the comparison of analytical methods to measure ACE activity, enalaprilat and benazeprilat.  
J. Pharm. Sci., **82**, 471-474.
7. JR Wade, AW Kelman, CA Howie & B Whiting, 1993.  
Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis.  
J. Pharmacokin. Biopharm., **21**, 209-222.
8. NJ Macdonald, A Siofi, CA Howie, JR Wade & HL Elliott, 1993.  
The effects of age on the pharmacokinetics and pharmacodynamics of single oral doses of benazepril and enalapril.  
Br. J. Clin. Pharmacol., **36**, 205-209.
9. JR Wade, SL Beal, & NC Sambol, 1994.  
Interaction between the choice of structural, statistical and covariate models in population pharmacokinetic analysis.  
J. Pharmacokin. Biopharm., **22**, 165-177.
10. JR Wade & NC Sambol, 1995.  
Felodipine population dose-response and concentration-response relationships in essential hypertension.  
Clin. Pharmacol. Ther. **57**, 569-581.
11. EN Jonsson, JR Wade & MO Karlsson, 1996.  
Comparison of some practical sampling strategies for population pharmacokinetic studies.  
J. Pharmacokin. Biopharm., **24**, 245-263.
12. MO Karlsson, JR Wade, E Loumayer & A Munafo, 1997.  
A population model for the follicular growth in women treated with follicle stimulating hormone.  
Clin. Pharmacol. Ther., **62**, 665-674.
13. EN Jonsson, JR Wade, G Almqvist & MO Karlsson, 1997.

- Discrimination between rival dosing histories.  
Pharm. Res. **14**, 984-991.
14. MO Karlsson, JR Wade, E Loumayer & A Munafo, 1998.  
The population pharmacokinetics of recombinant- and urinary-human follicle stimulating hormone in women.  
Br. J. Clin. Pharmacol. **45**, 13-20.
  15. MO Karlsson, EN Jonsson, CG Wiltse & JR Wade, 1998.  
Assumptions testing in population pharmacokinetic models: Illustrated with an analysis of moxonidine data from congestive heart failure patients.  
J. Pharmacokin. Biopharm., 26, 227-266.
  16. E. Niclas Jonsson, Janet R. Wade, Mats O. Karlsson, 2000.  
Nonlinearity Detection: Advantages of Nonlinear Mixed-Effects Modeling.  
AAPS Pharmsci; **2** (3) article 32 (<http://www.pharmsci.org/>)
  17. JR Wade, M Edholm & T Salmonsén, 2005.  
A guide for reporting the results of population pharmacokinetic analyses: A Swedish perspective.  
AAPS Journal, 2005; 07(02), article 45.  
[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750982/pdf/12248\\_2008\\_Article\\_72456.pdf](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750982/pdf/12248_2008_Article_72456.pdf)
  18. E Snoeck, JR Wade, F Duff, M Lamb & K Jorga, 2006.  
Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with perinterferon alfa-2a (40KD) plus ribavirin.  
Br. J. Clin. Pharmacol; 62, 699-709.
  19. JR Wade, E Snoeck, F Duff, M Lamb & K Jorga, 2006.  
Pharmacokinetics of ribavirin in patients with hepatitis C virus.  
Br. J. Clin. Pharmacol; 62, 710-714.  
<http://www.blackwell-synergy.com/doi/full/10.1111/j.1365-2125.2006.02704.x>
  20. P Jacqmin, L McFadyen & JR Wade. 2008.  
A receptor theory-based semimechanistic PD model for the CCR5 noncompetitive antagonist maraviroc.  
Br J Clin Pharmacol., 65(S1), 95-106.
  21. P Jacqmin, L McFadyen & JR Wade. 2010. Basic PK/PD principles of drug effects in circular/proliferative systems for disease modelling. J. Pharmacokin. Biopharm 37:157-177.  
<http://www.springerlink.com/content/m88q135028268706/fulltext.pdf>
  22. Kakuda TN, Wade JR, Snoeck E, Vis P, Schöller-Gyüre M, Peeters MP, Corbett C, Nijs S, Vingerhoets J, Leopold L, De Smedt G, Woodfall BJ, Hoetelmans RM. 2010.  
Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients.  
Clin. Pharmacol. Ther. 88(5), 695-703.
  23. Jacqmin P, Wade JR, Weatherley B, Snoeck E, Marshall S, McFadyen L. 2013.  
Assessment of Maraviroc exposure-response relationship at 48 weeks in treatment-experienced-HIV-1-infected patients in the MOTIVATE studies.  
CPT: Pharmacometrics & Systems Pharmacology (2013) 2, e64;  
doi:10.1038/psp.2013.42. Published online 14 August 2013.
  24. Wade JR, Parker G, Kosutic G, Feagen BG, Sandborn WJ, Laveille C, Oliver R. 2015.  
Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease. J Clin Pharmacol. 2015, 55(8), 866-874.
  25. Patel G, King A, Dutta S, Korb S, Wade JR, Foulds P, Sumeray M. 2016.  
Evaluation of the effects of the weak CYP3A inhibitors atorvastatin and ethinyl

- estradiol/norgestimate on lomitapide pharmacokinetics in healthy subjects. *J Clin Pharmacol.* 2016; 56(1): 47-55.
26. Bonate PL, Ahamadi M, Budha N, de la Peña A, Earp JC, Hong Y, Karlsson MO, Ravva P, Ruiz-Garcia A, Struemper H, Wade JR. 2016. Methods and strategies for assessing uncontrolled drug–drug interactions in population pharmacokinetic analyses: results from the International Society of Pharmacometrics (ISOP) Working Group. *J Pharmacokinet Pharmacodyn* 2016; 43(2): 123-135.
  27. Schoemaker R, Wade JR, Stockis A. 2016. Brivaracetam population pharmacokinetics and exposure-response modeling in adult subjects with partial-onset seizures. *J Clin Pharmacol* 2016; 56(12):1591-1602.
  28. Schoemaker R, Wade JR, Stockis A. 2017. Brivaracetam population pharmacokinetics in children with epilepsy aged 1 month to 16 years. *Eur J Clin Pharmacol* 2017; 73(6): 727-733.  
[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423986/pdf/228\\_2017\\_Article\\_2230.pdf](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423986/pdf/228_2017_Article_2230.pdf)
  29. Schoemaker R, Wade JR, D'Souza J, Stockis A. 2017. Evaluation of brivaracetam efficacy as monotherapy in adult patients with focal seizures. *Epilepsy Research* 2017; 137: 95-100.  
<https://doi.org/10.1016/j.eplepsyres.2017.09.014>
  30. Schoemaker R, Wade JR, Stockis A. 2018. Extrapolation of a brivaracetam exposure–response model from adults to children with focal Seizures. *Clinical Pharmacokinetics* 2018; 57(7):843-854.  
[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999174/pdf/40262\\_2017\\_Article\\_597.pdf](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999174/pdf/40262_2017_Article_597.pdf)
  31. Wilkins JJ, Brockhaus B, Dai H, Vugmeyster Y, White JT, Brar S, Bello CL, Neuteboom B, Wade JR, Girard P, Khandelwal A. 2019. Time-varying clearance and impact of disease state on the pharmacokinetics of avelumab in Merkel cell carcinoma and urothelial carcinoma. *CPT-PSP.* 2019; 8: 415-427.
  32. Alifrangis L, Schoemaker R, Skartved NJ, Hald R, Montagut C, Kopetz S, Tabernero J, Kragh M, Wade JR. 2020. Population pharmacokinetics and covariate analysis of Sym004, an antibody mixture against the epidermal growth factor receptor, in subjects with metastatic colorectal cancer and other solid tumors. *J Pharmacokinet Pharmacodyn.* 2020 Feb;47(1):5-18. doi: 10.1007/s10928-019-09663-2. Epub 2019 Nov 2. PMID: 31679083.
  33. Yoshida K, Wilkins J, Winkler J, Wade JR, Kotani N, Wang N, Sane R, Chanu P. 2021. Population Pharmacokinetics of Ipatasertib and Its Metabolite in Cancer Patients. *J Clin Pharmacol.* 2021 Jul 17. doi: 10.1002/jcph.1942. Online ahead of print. PMID: 34273118.
  34. Kotani N, Wilkins JJ, Wade JR, Dang S, Sutaria DS, Yoshida K, Sundrani S, Ding H, Garcia J, Hinton H, Sane R, Chanu P. Characterization of exposure-response relationships of ipatasertib in patients with metastatic castration-resistant prostate cancer in the IPATential150 study. *Cancer Chemother Pharmacol.* 2022 Dec;90(6):511-521. doi: 10.1007/s00280-022-04488-2. Epub 2022 Oct 28. PMID: 36305957; PMCID: PMC9637074.

## Book Chapters

1. JR Wade, 1997.  
Population pharmacokinetics/pharmacodynamics: European regulatory experiences.  
In 'New strategies in drug development and clinical evaluation. The population approach.'. Luxembourg: Office for official publications of the European Communities.
2. JR Wade, 1999.  
Regulatory prospects for in vitro studies of drug metabolism.  
In 'European symposium on the prediction of drug metabolism in man: progress and problems.' Luxembourg: Office for official publications of the European Communities.
3. T Salmonson & JR Wade, 1999.  
Management of variability – Regulatory aspects.  
In 'Variability in human drug response', edited by G.T. Tucker. International Congress Series No. 1178, Elsevier Science B.V., Amsterdam.
4. JR Wade, 2006.  
European view on the role of PK/PD in drug approval – Discussion on the basis of examples.  
In 'Measurement and Kinetics of In Vivo drug effects: Advances in Simultaneous pharmacokinetic/pharmacodynamic modeling', edited by M Danhof, DR Stanski & P Rolan. Leiden/Amsterdam Center for Drug Research. ISBN 90-74538-64-9.
5. P Jacqmin & JR Wade, 2010.  
Dosing schedules – General principles.  
In 'Measurement and Kinetics of In Vivo drug effects: Advances in Simultaneous pharmacokinetic/pharmacodynamic modeling', edited by M Danhof, PH van der Graaf & NHG Holford. Leiden/Amsterdam Center for Drug Research. ISBN 978-90-74538-73-2.